天然产物研究与开发 ›› 2025, Vol. 37 ›› Issue (3): 555-565.doi: 10.16333/j.1001-6880.2025.3.019 cstr: 32307.14.1001-6880.2025.3.019

• 数据研究 • 上一篇    下一篇

基于网络药理学的灯盏花乙素抗乳腺癌机制研究及实验验证

田冲冲,张 琦,刘开娜,方晨曦,包小波*   

  1. 江苏医药职业学院药学院,盐城 224005

  • 出版日期:2025-04-01 发布日期:2025-04-01
  • 基金资助:
    江苏省盐城市卫生健康委员会2023年度医学科研立项项目(YK2023032);江苏高校哲学社会科学研究一般项目(2022SJY B2075);江苏医药职业学院自然科学基金研究重点项目(20214107)

Mechanism of scutellarin on breast cancer based on network pharmacology and in vitro experiments

TIAN Chong-chong,ZHANG Qi,LIU Kai-na,FANG Chen-xi,BAO Xiao-bo*#br#   

  1. Department of Pharmacy,Jiangsu Medical College of Medicine,Yancheng 224005,China

  • Online:2025-04-01 Published:2025-04-01

摘要:

采用网络药理学和分子对接技术预测灯盏花乙素(scutellarinSCU)抗乳腺癌的潜在靶点和作用机制,并结合临床数据以及体外细胞实验进行验证。分别通过SwissTargetPrediction数据库、TargetNet数据库以及GeneCardsOMIMTTD数据库筛选SCU的潜在作用靶点和乳腺癌相关疾病靶点,然后利用Venny2.1.0平台获得药物和疾病的交集靶标,作为SCU干预乳腺癌的潜在治疗靶点;通过STRING数据库和Cytoscape 3.7.2软件构建蛋白质-蛋白质互作网络并筛选关键靶点;利用DAVID数据库对交集靶标进行基因本体(GO)功能富集与京都基因与基因组百科全书(KEGG)通路富集分析;利用Autodock Vina软件对排名前两位的核心靶点与SCU进行分子对接验证;通过癌症基因组图谱(TCGA)数据库分析核心靶基因在临床样本中的表达情况;最后在细胞水平验证SCU对乳腺癌的抗增殖作用以及对前面获取的关键靶点和通路蛋白表达的影响。经数据库筛选得到90SCU抗乳腺癌潜在靶点,后续拓扑分析得到度值排名前5的关键靶点,分别为EGFRTNFCASP3PTGS2以及MAPK14KEGG通路分析提示SCU抗乳腺癌主要涉及C-型凝集素受体信号通路、凋亡信号通路、人巨细胞病毒感染、HIF-1信号通路、IL-17等多条信号通路;分子对接结果显示SCU与关键靶点具有较强的结合能力;临床样本分析显示与健康人群相比,关键靶基因的表达均在乳腺癌患者中发生显著变化(P < 0.01)。体外细胞实验表明,SCU40~160 μmol/L浓度范围内以剂量依赖性的方式抑制人乳腺癌细胞MCF-7细胞的增殖(P < 0.01P < 0.05)Western blot结果显示SCU上调了MCF-7细胞中EGFR的蛋白表达,下调了TNF-α HIF-1 α 的蛋白表达。综上, SCU干预乳腺癌具有多靶点、多通路的特点,其作用机制可能与下调TNF-α /HIF-1 α 、上调EGFR通路,继而抑制细胞增殖有关,从而为SCU临床研究和产品开发提供了理论依据和参考。

关键词: 灯盏花乙素, 乳腺癌, 网络药理学, 分子对接, 体外细胞实验, 信号通路

Abstract:

Network pharmacology,molecular docking and experimental validation were employed to explore the potential therapeutic targets and mechanisms of scutellarin (SCU) in the treatment of breast cancer.The targets of SCU were predicted through SwissTargetPrediction database and TargetNet database,and the potentical anti-breast cancer targets of SCU were obtained by mapping them with the potential targets associated with breast cancer retrieved from GeneCards,OMIM,TTD databases.The STRING database was applied to construt the protein-protein interaction networks and topological analysis was performed by Cytoscape 3.7.2 software.GO functional enrichment analysis and KEGG pathway enrichment analysis of intersecting targets was carried out using the DAVID database.The building of SCU to key targets was validated through molecular docking study using Autodock Vina software.The expression of relevant target genes in Clinical case samples obtained from the Cancer Genome Atlas (TCGA) database were analyzed.At last,CCK-8 assay was performed to explore the anti-proliferative effect of SCU under different concentrations and the effects of SCU on the protein expression of TNF-α,EGFR and HIF-1α signaling pathway in human breast adenocarcinoma MCF-7 cells were examined by Western blot.As a result,a total of 90 potential targets were screened out,and five key targets were obtained after topological analysis,among which EGFR,TNF,CASP3,PTGS2,and MAPK14 are closely related to the anti-breast cancer effect of SCU.Multiple signaling pathways such as C-type lectin receptor signaling pathway,Apoptosis,Human cytomegalovirus infection,HIF-1 signaling pathway and IL-17 signaling pathway were involved in the anti-breast cancer effect of SCU.Molecular docking results showed that SCU has an excellent binding effect with key target proteins EGFR and TNF.The results of clinical samples revealed that the key target genes were significantly changed in breast caner patients compared with the healthy population.In vitro cell experiments showed that SCU (40-160 μmol/L) significantly inhibited the proliferation of human breast adenocarcinoma MCF-7 cells in a dose-dependent manner (P < 0.01 or P < 0.05).Further western blot assay confirmed SCU up-regulated EGFR protein expression and down-regulated TNF-α  and HIF-1 α  protein expression.In conclusion,SCU exerts anti-cancer effect through multiple targets and signal pathways.This study provided a theoretical basis and reference for the exploration of SCU on clinical research and product development.

Key words: scutellarin, breast cancer, network pharmacology, molecular docking, in vitro cellular experiment, signaling pathway

中图分类号:  R739.5